Dear all,
when articles talk about "co-primary endpoints" in clinical trials, what do they generally mean? Does this refer to two (or more) endpoints, all of which are considered "primary" and all of which are required (in a superiority setting, for example) to show superiority of treatment over placebo? If any of you is aware of any references (in the statistical literature), I would be most grateful.
With kind regards
Markus
|